Modeling idiosyncrasy: A novel animal model of drug-induced liver injury

Hepatology

Volumn 61, Issue 4, 2015, Pages 1124-1126

  Webb, Gwilym J ^a   Adams, David H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMODIAQUINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUTATHIONE; IPILIMUMAB; LIPOPOLYSACCHARIDE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN SH3; UBIQUITIN PROTEIN LIGASE E3;

ACUTE LIVER FAILURE; ARTICLE; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL FUNCTION; DOWN REGULATION; DRUG BIOAVAILABILITY; HEMATOPOIETIC CELL; HUMAN; HYPERTRANSAMINASEMIA; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; LIVER TOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXIC HEPATITIS; UNITED STATES; ANIMAL;

ANIMALS;

EID: 84925365844     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27617     Document Type: Article

References (21)

1. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2009;89:806-815.
2. Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury-current status. Crit Rev Toxicol 2011;41:723-739.
3. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014;146:914-928.
4. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-3053.
5. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-2076.
6. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010;85:349-356.
7. -/- mice with amodiaquine and anti-CTLA-4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015;61:1332-1342.
8. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-1425.
9. Kerb R, Fux R, Mörike K, Kremsner PG, Gil JP, Gleiter CH, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9:760-774.
10. Metushi IG, Cai P, Dervovic D, Liu F, Lobach A, Nakagawa T, et al. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset. J Immunotoxicol 2014:1-14.
11. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
12. -/- T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta. J Immunol 2010;185:2051-2058.
13. Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011;11:852-863.
14. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
15. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-5309.
16. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014:1-9.
17. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013;2013:1-19.
18. Shimizu S, Atsumi R, Itokawa K, Iwasaki M, Aoki T, Ono C, et al. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch Toxicol 2009;83:701-707.
19. Yokoyama A, Mori S, Takahashi HK, Kanke T, Wake H, Nishibori M. Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol 2007;558:179-184.
20. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-819.
21. Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010;184:2886-2898.